Maplight Therapeutics (NASDAQ:MPLT) Now Covered by Analysts at TD Cowen

Analysts at TD Cowen began coverage on shares of Maplight Therapeutics (NASDAQ:MPLT) in a research note issued on Tuesday. The brokerage set a “buy” rating on the stock.

Several other equities research analysts also recently weighed in on the company. Wall Street Zen downgraded Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 target price on the stock. Finally, Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.80.

Maplight Therapeutics Stock Performance

Shares of NASDAQ MPLT opened at $22.61 on Tuesday. The business has a 50 day simple moving average of $18.25. Maplight Therapeutics has a fifty-two week low of $12.24 and a fifty-two week high of $22.94. The stock has a market capitalization of $959.48 million and a P/E ratio of -0.57.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($1.42).

Insider Transactions at Maplight Therapeutics

In related news, Director George Pavlov bought 10,658 shares of Maplight Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were acquired at an average cost of $17.48 per share, with a total value of $186,301.84. Following the completion of the transaction, the director owned 10,658 shares in the company, valued at $186,301.84. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert C. Malenka sold 21,262 shares of Maplight Therapeutics stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $18.55, for a total transaction of $394,410.10. Following the transaction, the director directly owned 371,885 shares in the company, valued at approximately $6,898,466.75. The trade was a 5.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have purchased 39,124 shares of company stock valued at $693,846 and have sold 74,612 shares valued at $1,368,065.

Hedge Funds Weigh In On Maplight Therapeutics

Several institutional investors have recently bought and sold shares of the business. Fcpm Iii Services B.V. purchased a new position in Maplight Therapeutics during the fourth quarter valued at approximately $56,672,000. T. Rowe Price Investment Management Inc. purchased a new position in Maplight Therapeutics during the fourth quarter valued at approximately $49,154,000. Goldman Sachs Group Inc. purchased a new position in Maplight Therapeutics during the fourth quarter valued at approximately $34,026,000. Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics during the fourth quarter valued at approximately $17,060,000. Finally, 5AM Venture Management LLC purchased a new position in Maplight Therapeutics during the fourth quarter valued at approximately $16,687,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.